Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. ADR (NQ: CLLS )

2.010 +0.010 (+0.50%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cellectis S.A. ADR

< Previous 1 2 3 4 Next >
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
Why Is Calyxt (CLXT) Stock Up 140% Today?
Calyxt (CLXT) stock is rocketing higher on Tuesday after the company signed an all-stock merger agreement with Cibus Global. 
Via InvestorPlace
5 Most Expensive Health Care Stocks You Should Worry About
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
Gainers 
Via Benzinga
Cellectis Touts Positive Preliminary Data From Two Leukemia Trials
Via Benzinga
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
Via Benzinga
Recap: Cellectis Q4 Earnings
Cellectis (NASDAQ:CLLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cellectis... 
Via Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. 
Via Benzinga
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
Cellectis's Earnings Outlook
Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Cellectis will... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket
Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Akanda (NASDAQ:AKAN) stock rose 27.1% to $0.52 during Friday's pre-market session. The company's market cap stands at $16.0 million. 
Via Benzinga
11 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million. 
Via Benzinga
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. 
Via Benzinga
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day... 
Via Benzinga
Why T2 Biosystems Is Trading Higher By 18%; Here Are 28 Stocks Moving Premarket
Gainers HHG Capital Corporation (NASDAQ: HHGC) shares rose 42.1% to $14.56 in pre-market trading. 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Cellectis Gets FDA Nod For Initial-Stage Non-Hodgkin Lymphoma Study
The U.S. Food and Drug Administration (FDA) has announced clearance to Cellectis' (NASDAQ: CLLS) Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of UCART20x22 for... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
71 Biggest Movers From Yesterday
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation... 
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut
Via Benzinga
Cellectis Reveals Preclinical Data On First Allogeneic Dual CAR T-Cell Product In Non-Hodgkin Lymphoma
Via Benzinga
A Preview Of Cellectis's Earnings
Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.